Co-Diagnostics (CODX) to Sell 3.3M Shares at $3.08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Co-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-the-Market
February 11, 2020 8:00 AM ESTSALT LAKE CITY--(BUSINESS WIRE)-- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,324,676 shares of its common stock, at a purchase price per share of $3.08, in a registered direct offering priced at-the-marked under the Nasdaq rules. The closing of the offering is expected to occur on or about February 13, 2020, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is... More
